Form 4: OBIO Director Awarded 15,000 RSUs

Orchestra BioMed Holdings, Inc. Director David Pacitti received an award of 15,000 restricted stock units, vesting one year from the grant date.

Summary

• Director David Pacitti was awarded 15,000 Restricted Stock Units (RSUs) on August 7, 2025.
• Each RSU represents a contingent right to receive one share of Orchestra BioMed Holdings, Inc. Common Stock.
• The RSUs will vest on August 7, 2026, which is the one-year anniversary of the grant date.
• Vesting is contingent upon Mr. Pacitti's continuous service to the company through the vesting date.
• Following this award, Mr. Pacitti beneficially owns 44,968 shares of Common Stock.

Sentiment

Score: 7

Explanation: The RSU award is a standard compensation practice that aligns director interests with shareholders and aids in retention, which is generally positive for corporate governance and stability. The minor dilution is an expected trade-off for such benefits.

Positives

• The RSU award aligns the director's interests with long-term shareholder value through equity ownership.
• It serves as a retention mechanism, incentivizing the director to remain with the company for at least one year.

Negatives

• The future issuance of 15,000 shares upon vesting will result in a minor dilution of existing shareholder equity.

Future Outlook

The 15,000 Restricted Stock Units are scheduled to vest on August 7, 2026, contingent on the director's continuous service.

Industry Context

This is a routine compensation event for a director, common across publicly traded companies to align management and director incentives with shareholder interests. It does not directly reflect broader industry trends beyond standard corporate governance practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential future dilution upon vesting, but improved alignment of director interests with long-term shareholder value.

Next Steps

• The 15,000 Restricted Stock Units will vest on August 7, 2026, subject to the director's continuous service.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation award to a director, which is a standard practice for aligning interests and retention. It does not present new information that would fundamentally alter the investment thesis for Orchestra BioMed Holdings, Inc., warranting a "hold" recommendation as it's an expected operational event.

Keywords

Orchestra BioMed Holdings, OBIO, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Award, Insider Transaction, David Pacitti